FK-506, A NOVEL IMMUNOSUPPRESSANT ISOLATED FROM A STREPTOMYCES .2. IMMUNOSUPPRESSIVE EFFECT OF FK-506 INVITRO
FK-506, A NOVEL IMMUNOSUPPRESSANT ISOLATED FROM A STREPTOMYCES .2. IMMUNOSUPPRESSIVE EFFECT OF FK-506 INVITRO
复制标题
DOI：
10.7164/antibiotics.40.1256
复制
发表时间：
1987-09-01
影响因子：
3.3
通讯作者：
OCHIAI, T
中科院分区：
文献类型：
--
作者：
KINO, T;HATANAKA, H;OCHIAI, T
本文介绍了一种由链霉菌产生的新型免疫抑制剂FK-506的免疫药理学特性。我们继续测试该制剂对各种体外免疫系统的影响。结果表明，该药对混合淋巴细胞反应、细胞毒T细胞生成、T细胞来源的可溶性介质白介素2(IL-2)、白介素3和γ-干扰素的产生及IL-2受体的表达均有抑制作用。FK-506和环孢素在所有试验中的IC50值分别约为0.1 nM和10 nM。因此，新型药物FK-506在体外抑制免疫系统的浓度比CS低约数百倍。
The immuno-pharmacological profile of a novel immunosuppressive agent, FK-506 produced by a streptomycete, is presented here. We proceeded to test the effect of the agent on various in vitro immune systems. It showed that mixed lymphocyte reaction, cytotoxic T cell generation, the production of T cell-derived soluble mediators such as interleukin 2 (IL-2), interleukin 3 and gamma-interferon and the expression of the IL-2 receptor were suppressed by this agent. The IC50 values of FK-506 and cyclosporin (CS) in all tests were approximately 0.1 nM and 10 nM, respectively. Therefore, the novel agent, FK-506 suppressed in vitro immune systems at about hundred times lower concentration than CS.